BRKR

Business Context and Reporting Period

Company: Bruker Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2008
Business Overview: Bruker designs, manufactures, and services life science and materials research systems based on X-ray, magnetic resonance, mass spectrometry, and optical emission spectroscopy technologies. Following the February 26, 2008, acquisition of Bruker BioSpin (a combination of companies under common control), the Company reports results in two segments: BioScience (X-ray, mass spec, spectroscopy) and BioSpin (magnetic resonance, superconductor wires).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 30.7% ($73.1M) for the quarter and 23.3% ($104.0M) for the six months compared to 2007. Organic growth (excluding foreign exchange) was 19.4% for the quarter and 12.7% for the six months.
• Profitability: While operating income increased, operating margins for the six months declined to 8.1% from 9.3% in the prior year. This was driven by $6.2M in acquisition-related charges and increased operating expenses.
• Net Income Decline (6mo): Net income for the six months dropped to $21.0M from $32.0M in the prior year, primarily due to $9.0M in foreign exchange losses and increased interest expense from acquisition debt.
• Debt Increase: Total debt surged from $44.2M at year-end 2007 to $242.2M at June 30, 2008, following the financing of the Bruker BioSpin acquisition.
• Foreign Exchange Impact: The Company recorded $9.0M in net foreign currency transaction losses for the six months ended June 30, 2008, compared to $0.5M in gains in the prior year, largely due to the weakening of the U.S. Dollar and Euro.

Guidance, Outlook, and Risks

• Management Commentary: Management intends to refocus on gross margin improvement programs and implement cost-saving measures, including a partial hiring freeze, in the second half of 2008. They believe actions taken in Q2 will reduce the impact of foreign currency volatility in H2.
• Debt Covenants: The Company was not in compliance with one covenant related to a U.S. government agency debt arrangement as of June 30, 2008. A limited waiver was obtained on July 28, 2008, and the covenant was modified for the remainder of the year. No cross-defaults were triggered.
• Legal Proceedings:
  • Isis Pharmaceuticals: Bruker Daltonics filed suit against Isis regarding a manufacturing agreement dispute; counterclaims have been asserted.
  • Whistleblower Claim: A former employee (Brian Lamy) filed a federal lawsuit alleging termination in violation of the Sarbanes-Oxley Act. The Company's Audit Committee found no evidence of improper activity and intends to defend vigorously.
• Tax Risks: A Swiss entity is under audit for tax years 2003-2006; the outcome cannot be reasonably estimated. The Company maintains a full valuation allowance for U.S. net operating losses.

Investor Verification Checklist

• Debt Covenant Compliance: Verify the status of the modified covenant with the U.S. government agency and ensure no future breaches occur.
• Foreign Exchange Exposure: Assess the effectiveness of management's new hedging and settlement strategies in mitigating currency losses, given the significant impact on Q1 and Q2 results.
• Acquisition Integration: Monitor the realization of revenue synergies and margin improvements from the Bruker BioSpin acquisition against the backdrop of increased operating expenses.
• Legal Contingencies: Track the progress of the Isis Pharmaceuticals litigation and the Brian Lamy whistleblower lawsuit for potential financial impact.
• Working Capital: Review the significant drawdown in cash and cash equivalents (from $332M to $125M) and the reliance on credit facilities for liquidity.